An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab

- Bispecificity of therapeutic anti-Ang2/VEGF-CrossMab allows for specific depletion.
- Immunodepletion eliminates anti-Ang2/VEGF-CrossMab along with drug-bound Ang2.
- Drug capturing uses an anti-idiotypic antibody specific for the VEGF binding site.
- Free Ang2 determination uses immunodepletion prior to established Ang2 measurement.
- Reduced free Ang2 levels in patient samples confirm the mode of action of the drug.